Staffers are set to move to their new digs in east London in the middle of next year, shortly the EMA is scheduled to leave a neighboring building.

Takeda inked a multiyear, $170 million-per-program drug discovery partnership with Schrödinger.

Ex-Novo exec Høiland became Radius' CEO, ex-Sanofi Genzyme CEO Meeker joined Trevi as chairman, Myovant tapped four execs with Big Pharma experience.

The positive narrative spun by Ironwood’s management failed to convince investors, who seized on perceived underwhelming efficacy data.

Check out the rest of Thursday's news of note.

Belgian biotech Ablynx signed a deal with Sanofi that could be worth an eye-watering €2.4 billion, although just €23 million of that comes up front.

The dumping of LSD1 inhibitor ORY-1001 wiped as much as 30% off Oryzon’s stock price as investors digested the loss of the $500 million-plus deal.

NeuroVia gets $14 million to treat rare CNS disorder X-linked adrenoleukodystrophy.

The trial suggests revefenacin has a tolerable safety profile comparable to that of Boehringer Ingelheim’s bronchodilator Spiriva.